[
    [
        {
            "time": "2023-10-15",
            "original_text": "孙飘扬回归首秀：恒瑞医药14亿重金“引进”普那布林，能否扛起业绩“大旗”？",
            "features": {
                "keywords": [
                    "孙飘扬",
                    "恒瑞医药",
                    "普那布林",
                    "业绩"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "孙飘扬回归首秀：恒瑞医药14亿重金“引进”普那布林，能否扛起业绩“大旗”？",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "北向资金连续10日扫货累计加仓近460亿，药明康德、隆基股份净买入均超8亿元",
            "features": {
                "keywords": [
                    "北向资金",
                    "药明康德",
                    "隆基股份",
                    "加仓"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "新能源"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北向资金连续10日扫货累计加仓近460亿，药明康德、隆基股份净买入均超8亿元",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "恒瑞医药(600276.SH)子公司HR20033片获药物临床试验批准",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "HR20033片",
                    "临床试验",
                    "批准"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药(600276.SH)子公司HR20033片获药物临床试验批准",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "恒瑞医药：药品HR20033片获临床试验批准通知书",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "HR20033片",
                    "临床试验",
                    "批准通知书"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药：药品HR20033片获临床试验批准通知书",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-09-02",
            "original_text": "A股融资融券日报：两融余额增加43.73亿元（9月2日）",
            "features": {
                "keywords": [
                    "两融余额",
                    "增加"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "市场整体"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股融资融券日报：两融余额增加43.73亿元（9月2日）",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "医药生物行业跟踪报告：创新药系列研究 PD-1/L1普药化 国内IO市场如何演绎",
            "features": {
                "keywords": [
                    "医药生物",
                    "创新药",
                    "PD-1/L1",
                    "普药化",
                    "IO市场"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业跟踪报告：创新药系列研究 PD-1/L1普药化 国内IO市场如何演绎",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]